Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06085287

Electromagnetic Therapy for Autism Spectrum Disorder

Electromagnetic Therapy for Autism Spectrum Disorder: a Pilot Randomized Controlled Trial

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
The University of Hong Kong · Academic / Other
Sex
All
Age
3 Years – 12 Years
Healthy volunteers
Not accepted

Summary

The investigators hypothesize that electromagnetic therapy (EMT) could produce greater improvement on Autism spectrum disorder (ASD) compared to the waitlist control. To test this hypothesis, a pilot randomized waitlist-controlled trial is designed to achieve the 2 aims: 1. To evaluate the efficacy of EMT in improving children with ASD as measured by Childhood Autism Rating Scale (CARS) by comparing the change in CARS scores from baseline to week 12 between the two groups. 2. To assess the safety of EMT by comparing the number of participants with adverse events, number of participants withdrawn and reasons of withdrawal in treatment group with those in the control group. A pilot randomized waitlist-controlled trial is designed. A total of 30 children aged 3-12 years with a principal diagnosis of ASD will be recruited. They will be randomly assigned to Care-As Usual (CAU) and CAU+EMT groups (n = 15 each group). Participants on the CAU+EMT group will receive a total of 30 sessions of EMT within 12 weeks (2 - 3 sessions/week).Those who are initially assigned to CAU group will receive EMT for 12 weeks after they complete the trial. The post-trial treatment will serve as a compensation for their participation.

Conditions

Interventions

TypeNameDescription
DEVICEElectromagnetic therapyElectromagnetic therapy will be performed using an electromagnetic stimulator (Smart Cap). Chinese medicine practitioners who have at least 3 years of experience will conduct EMT after training. Each session of EMT will take 20-25 min, with 2-3 sessions per week, total of 30 sessions finished within 12 weeks.

Timeline

Start date
2024-03-01
Primary completion
2025-06-01
Completion
2025-12-31
First posted
2023-10-16
Last updated
2024-05-08

Locations

1 site across 1 country: Hong Kong

Source: ClinicalTrials.gov record NCT06085287. Inclusion in this directory is not an endorsement.